Abstracts tagged "Amyopathic dermatomyositis"

Abstract Number: 2328 • 2016 ACR/ARHP Annual Meeting
Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis
Kazuhiro Kurasawa¹, Satoko Arai¹, Yumeko Namiki¹, Ayae Tanaka¹, Ryutaro Yamazaki², Harutsugu Okada¹, Takayoshi Owada¹, Masafumi Arima¹ and Reika Maezawa¹, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan
Background/Purpose: Anti-MDA5 Ab positive dermatomyositis (DM) is a unique subset of inflammatory myopathy characterized by non- or mild muscle weakness, skin manifestation such as…
Abstract Number: 304 • 2015 ACR/ARHP Annual Meeting
Abnormal Pulmonary Function Tests, Interstitial Lung Disease, and Lung Function Decline in Patients with Classic and Clinically Amyopathic Dermatomyositis
Michael George¹, Maryl Kreider², Rupal Shah², Wallace Miller Jr.³, Peter A. Merkel⁴ and Victoria Werth^5,6, ¹Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Pulmonary, Allergy & Critical Care, University of Pennsylvania, Philadelphia, PA, ³Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Veterans Affairs Medical Center, Philadelphia, PA, ⁶Dermatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) is common in classic dermatomyositis (DM) and clinically amyopathic dermatomyositis (CADM), in which rash is present without weakness. Previous studies…
Abstract Number: 2370 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Anti-MDA5 (+) Dermatomyositis Patients in North America
Siamak Moghadam-Kia¹, Chester V. Oddis², Shinji Sato³, Masataka Kuwana⁴ and Rohit Aggarwal⁵, ¹Medicine-Myositis Center and Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, Tokai University School of Medicine, Isehara, Japan, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Clinically amyopathic dermatomyositis (CADM) patients have the classic rash (es) of DM but no objective proximal muscle weakness. Asian studies report a unique clinical phenotype in anti-MDA5…
Abstract Number: 2226 • 2014 ACR/ARHP Annual Meeting
Systemic Treatment for Clinically Amyopathic Dermatomyositis
Janice Lin¹, Alisa Femia², Mital Patel¹, Joseph Merola¹ and Ruth Ann Vleugels¹, ¹Dermatology, Brigham and Women's Hospital, Boston, MA, ²Dermatology, NYU Langone Medical Center, New York, NY
Background/Purpose: Clinically amyopathic dermatomyositis (CADM) is an important subset and accounts for approximately 20% of patients with dermatomyositis (DM). CADM is characterized by the presence…
Abstract Number: 2229 • 2014 ACR/ARHP Annual Meeting
How Often Are Clinically Amyopathic Dermatomyositis Patients Truly Amyopathic?
Edward J. Oberle^1,2, Michelle Bayer^3,4, Dominic O. Co^4,5 and Yvonne Chiu^4,5, ¹Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ²Rheumatology, Children's Hospital of Wisconsin, Milwaukee, WI, ³Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Children's Hospital of Wisconsin, Milwaukee, WI, ⁵Pediatrics, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder primarily involving the skin and striated muscle. Classic JDM presents with rash, proximal muscle weakness, and…
Abstract Number: 1266 • 2014 ACR/ARHP Annual Meeting
Anti-MDA5 Is Associated with Rapidly-Progressive Interstitial Lung Disease and Poor Survival in U.S. Patients with Amyopathic and Myopathic Dermatomyositis
Siamak Moghadam-Kia¹, Chester V. Oddis², Shinji Sato³, Masataka Kuwana⁴ and Rohit Aggarwal¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose : Clinically amyopathic dermatomyositis (CADM) is a subset of dermatomyositis (DM) presenting with the characteristic rash(es) of DM without objective muscle weakness. Asian studies…
Abstract Number: 1264 • 2014 ACR/ARHP Annual Meeting
Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Half of all polymyositis (PM)/dermatomyositis (DM) patients suffer from muscle weakness after initial treatment. Therefore, many patients with PM/DM have trouble with daily living…
Abstract Number: 2069 • 2013 ACR/ARHP Annual Meeting
Serum Interferon-α Is a Biomarker To Reflect The Disease Activity In Patients With Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Antibody-Positive Dermatomyositis
Yoshiro Horai¹, Tomohiro Koga², Keita Fujikawa³, Ayuko Takatani⁴, Ayako Nishino¹, Yoshikazu Nakashima⁵, Takahisa Suzuki⁵, Shin-ya Kawashiri¹, Naoki Iwamoto⁵, Kunihiro Ichinose⁶, Mami Tamai⁵, Hideki Nakamura⁵, Hiroaki Ida⁷, Yuji Ishimatsu⁸, Hiroshi Mukae⁹, Yasuhito Hamaguchi¹⁰, Manabu Fujimoto¹¹, Masataka Kuwana¹², Tomoki Origuchi¹³, Shigeru Kohno⁸ and Atsushi Kawakami⁵, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Arthritis and Connective Tissue Disease, Isahaya Health Insurance General Hospital, Isahaya, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Internal Medicine, Division of REspirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁸Department of Molecular Microbiology and Immunology, Nagasaki University School of Medicine, Nagasaki, Japan, Nagasaki, Japan, ⁹Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan, ¹⁰Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ¹¹Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ¹²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹³Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: The pathogenesis of anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM), which often complicates rapidly progressive interstitial lung disease (RPILD), is thought to…
Abstract Number: 2074 • 2013 ACR/ARHP Annual Meeting
The Analysis Of Prognostic Factors In Patients With Inflammatory Myopathies and Amyopathic Dermatomiositis Complicated With Interstitial Lung Disease
Maasa Hama¹, Yumiko Sugiyama¹, Yohei Kirino¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Reikou Kamiyama¹, Kaoru Minegishi¹, Ryusuke Yoshimi¹, Yukiko Asami¹, Atsuhisa Ueda¹, Mitsuhiro Takeno¹, Ichiro Aoki² and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Because interstitial lung disease (ILD) is one of the most critical manifestations and can be lethal in inflammatory myopathies (IM), especially amyopathic dermatomiositis (ADM),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].